Compare Becton Dickinson and Co (BDX) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs S&P500 ETF — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while S&P500 ETF trades at $753.65. The key difference: Becton Dickinson and Co pays a 2.79% dividend while S&P500 ETF pays none, and S&P500 ETF is trading nearer its 52-week high, Becton Dickinson and Co nearer its low. Which is the better fit depends on your goals.
| BDX | SPY | |
|---|---|---|
Market Cap | $41.51B | — |
Sector | Health | — |
52-Week High | $185.39 | $759.55 |
52-Week Low | $135.49 | $621.75 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
SPY trades at $749.08, down 0.77% on the day, with technical indicators showing a bullish bias from moving averages while oscillators remain neutral. The ETF approaches key resistance at $750 with support at $747. Recent news highlights analyst optimism with several firms projecting S&P 500 targets above 8,000 by year-end, though earnings season and inflation data remain key catalysts.
Outlook remains constructive given strong institutional sentiment and historical market performance, though risks include potential Fed policy shifts and valuation concerns. The dividend payment scheduled for July 31, 2026 provides income support, while technical consolidation near all-time highs suggests potential for breakout momentum if earnings deliver.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
